Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  JAMA Oncology

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2015.3730PMID 26562292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Compliance with National Comprehensive Cancer Network anti-emesis guidelines in a Community Hospital Cancer Center

  2016cited by this paper
• Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

  2015cited by this paper
• Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

  2015cited by this paper
• Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network

  2014cited by this paper
• Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.

  2014cited by this paper
• Preference weights for chemotherapy side effects from the perspective of women with breast cancer

  2013cited by this paper
• Abstract P3-09-02: Optimal anti-emetic choice for breast cancer patients receiving anthracycline and cyclophosphamide-based chemotherapy - A systematic review and network meta-analysis of randomized controlled trials

  2013cited by this paper
• Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

  2012cited by this paper
• Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

  2012cited by this paper
• Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

  2011cited by this paper
• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

  2010cited by this paper
• Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.

  2006cited by this paper
• Nausea: the neglected symptom?

  2004cited by this paper
• Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall

  2003cited by this paper

• Machine Learning‐Based Prediction Model for Delayed Chemotherapy‐Induced Nausea and Vomiting in Pediatric Cancer: A Prospective Cohort Study

  2026cites this paper
• Aprepitant use during chemotherapy and association with survival in women with early breast cancer

  2025cites this paper
• Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy

  2025influential citation
• Risk prediction model for chemotherapy-induced nausea and vomiting in cancer patients: a systematic review.

  2025cites this paper
• Clinical Decision Support Systems for cancer symptom management: A scoping review.

  2025cites this paper
• Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial.

  2025cites this paper
• [China guidelines on prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)].

  2024cites this paper
• To warrant clinical adoption AI models require a multi-faceted implementation evaluation

  2024cites this paper
• The design of studies testing the effectiveness of risk-guided care has many challenges: A scoping review addressing key considerations.

  2023cites this paper
• Determining the factors affecting chemotherapy-induced nausea and vomiting in children with cancer.

  2023cites this paper
• Distinct Nausea Profiles Are Associated With Gastrointestinal Symptoms in Oncology Patients Receiving Chemotherapy

  2022cites this paper
• A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

  2022cites this paper
• Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

  2022cites this paper
• Mitigating acute chemotherapy-associated adverse events in patients with cancer

  2022cites this paper
• Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy

  2022cites this paper
• Real‐world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database

  2021cites this paper
• Clinical impact and quality of randomized controlled trials involving interventions evaluating artificial intelligence prediction tools: a systematic review

  2021cites this paper
• The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design

  2021cites this paper
• Metagenomics and chemotherapy‐induced nausea: A roadmap for future research

  2021cites this paper
• Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

  2021cites this paper
• Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy.

  2021cites this paper
• Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting

  2021cites this paper
• Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer

  2021influential citation
• GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates.

  2020cites this paper
• Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials

  2020cites this paper
• Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis.

  2020cites this paper
• Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research

  2020cites this paper
• Antiemetic Guidelines: Not Just for the HEC of It.

  2020cites this paper
• A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

  2020cites this paper
• Risk factors for chemotherapy‐induced nausea in pediatric patients receiving highly emetogenic chemotherapy

  2019cites this paper
• Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors

  2018cites this paper
• Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study.

  2018cites this paper
• Guidelines versus individualized care for the management of CINV

  2018cites this paper
• Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.

  2018cites this paper
• Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.

  2018cites this paper
• The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

  2017cites this paper
• Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.

  2017cites this paper
• Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach.

  2017cites this paper
• Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

  2017cites this paper
• Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).

  2017cites this paper
• Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management

  2017cites this paper
• A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach

  2017cites this paper
• Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study.

  2016cites this paper
• Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting

  2016cites this paper
• Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors

  2016cites this paper
• Can Patient Risk Factors Outperform Antiemetic Guidelines?: Choosing Wisely.

  2016cites this paper
• Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting.

  2016cites this paper
• Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

  2016cites this paper
• Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.

  2015cites this paper